Trump Officials Reject FDA's Plan to Fast-Track Psychedelic Depression Treatment

The FDA proposed to fast-track the review of Compass Pathways' psychedelic treatment for severe depression, but Trump administration officials rejected the plan. This suggests possible internal differences between senior leadership and the "Make America Healthy Again" movement. The rejection of the proposal may indicate that the Trump administration is not fully supportive of psychedelic treatments for mental health conditions.